New combo aims to boost CAR-T cell staying power in lymphoma

NCT ID NCT07489989

Recruiting now Disease control Sponsor: Daihong Liu Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding chidamide and a PD-1 inhibitor after CAR-T cell therapy can help prevent relapse in people with relapsed or refractory diffuse large B-cell lymphoma. The study plans to enroll 30 participants. The goal is to see if this maintenance strategy improves how long patients stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chidamide and a PD-1 inhibitor (drug combination)
What this could lead to: If successful, this combination could reduce relapse rates and improve long-term survival for people with hard-to-treat B-cell lymphoma.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The added drugs also carry risks of side effects like immune overactivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.